Literature DB >> 19083076

Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia.

A Mardjuadi1, M Soedirman, Buddy Utoyo, J J Rasker.   

Abstract

A 31-year-old Chinese lady presented with severe SLE with nephrotic syndrome, anemia, leucopenia and thrombocytopenia, skin lesions, and joint inflammation after failing previous standard therapy. After treatment with three infusions of rituximab she showed immediate improvements regarding clinical and laboratory parameters. She received no cytotoxic drugs and remained well for at least 7 months, despite stopping prednisolone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19083076     DOI: 10.1007/s10067-008-1069-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  18 in total

Review 1.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

2.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Authors:  M J Leandro; G Cambridge; J C Edwards; M R Ehrenstein; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2005-09-27       Impact factor: 7.580

Review 3.  Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment.

Authors:  J Golbus; W J McCune
Journal:  Rheum Dis Clin North Am       Date:  1994-02       Impact factor: 2.670

Review 4.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

Review 5.  B-cell-directed therapies in systemic lupus erythematosus.

Authors:  Arlene T Tieng; Elena Peeva
Journal:  Semin Arthritis Rheum       Date:  2008-02-21       Impact factor: 5.532

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.

Authors:  Laurent Camous; Catherine Melander; Marion Vallet; Tarek Squalli; Bertrand Knebelmann; Laure-Hélène Noël; Fadi Fakhouri
Journal:  Am J Kidney Dis       Date:  2008-06-24       Impact factor: 8.860

8.  [Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus].

Authors:  S Lehembre; A Macario-Barrel; P Musette; P Carvalho; P Joly
Journal:  Ann Dermatol Venereol       Date:  2006-01       Impact factor: 0.777

9.  Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Authors:  Iva Gunnarsson; Birgitta Sundelin; Thorunn Jónsdóttir; Stefan H Jacobson; Elisabet Welin Henriksson; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2007-04

10.  Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

Authors:  Catharina Lindholm; Katharina Börjesson-Asp; Kiandokht Zendjanchi; Anna-Carin Sundqvist; Andrej Tarkowski; Maria Bokarewa
Journal:  J Rheumatol       Date:  2008-04-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.